Nampt/PBEF/visfatin serum levels: a new biomarker for retinal blood vessel occlusions
Simon Kaja,1,* Anna A Shah,1,* Shamim A Haji,1,* Krishna B Patel,1 Yuliya Naumchuk,1 Alexander Zabaneh,1 Bryan C Gerdes,1 Nancy Kunjukunju,1 Nelson R Sabates,1 Michael A Cassell,1 Ron K Lord,1 Kevin P Pikey,1 Abraham Poulose,1 Peter Koulen1,21Vision Research Center, Department of Ophthalmology, 2De...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2015
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/beebcfe6aec644fb9aa15fde17ab5a88 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:beebcfe6aec644fb9aa15fde17ab5a88 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:beebcfe6aec644fb9aa15fde17ab5a882021-12-02T06:08:35ZNampt/PBEF/visfatin serum levels: a new biomarker for retinal blood vessel occlusions1177-5483https://doaj.org/article/beebcfe6aec644fb9aa15fde17ab5a882015-04-01T00:00:00Zhttp://www.dovepress.com/namptpbefvisfatin-serum-levels-a-new-biomarker-for-retinal-blood-vesse-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483 Simon Kaja,1,* Anna A Shah,1,* Shamim A Haji,1,* Krishna B Patel,1 Yuliya Naumchuk,1 Alexander Zabaneh,1 Bryan C Gerdes,1 Nancy Kunjukunju,1 Nelson R Sabates,1 Michael A Cassell,1 Ron K Lord,1 Kevin P Pikey,1 Abraham Poulose,1 Peter Koulen1,21Vision Research Center, Department of Ophthalmology, 2Department of Basic Medical Science, School of Medicine, University of Missouri – Kansas City, Kansas City, MO, USA*These authors contributed equally to this workAbstract: The main objective of the study was to quantify serum levels of nicotinamide phosphoribosyltransferase (Nampt/pre-B-Cell colony-enhancing factor 1/visfatin) in subjects with a history of retinal vascular occlusions (RVOs), disease conditions characterized by pronounced ischemia, and metabolic energy deficits. A case–control study of 18 subjects with a history of RVO as well as six healthy volunteers is presented. Serum Nampt levels were quantified using a commercially available enzyme-linked immunosorbent assay kit. Serum Nampt levels were 79% lower in patients with a history of RVO compared with that in healthy volunteers (P<0.05). There was no statistically significant difference among the types of RVOs, specifically branch retinal vein occlusions (n=7), central retinal vein occlusions (n=5), hemiretinal vein occlusions (n=3), and central retinal artery occlusions (n=3; P=0.69). Further studies are needed to establish the temporal kinetics of Nampt expression and to determine whether Nampt may represent a novel biomarker to identify at-risk populations, or whether it is a druggable target with the potential to ameliorate the long-term complications associated with the condition, ie, macular edema, macular ischemia, neovascularization, and permanent loss of vision.Keywords: Nampt, PBEF, visfatin, nicotinamide phosphoribosyltransferase, pre-B-cell colony-enhancing factor, retinal artery occlusion, retinal vein occlusion, biomarker, retina, vasculatureKaja SShah AAHaji SAPatel KBNaumchuk YZabaneh AGerdes BCKunjukunju NSabates NRCassell MALord RKPikey KPPoulose AKoulen PDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2015, Iss default, Pp 611-618 (2015) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Ophthalmology RE1-994 |
| spellingShingle |
Ophthalmology RE1-994 Kaja S Shah AA Haji SA Patel KB Naumchuk Y Zabaneh A Gerdes BC Kunjukunju N Sabates NR Cassell MA Lord RK Pikey KP Poulose A Koulen P Nampt/PBEF/visfatin serum levels: a new biomarker for retinal blood vessel occlusions |
| description |
Simon Kaja,1,* Anna A Shah,1,* Shamim A Haji,1,* Krishna B Patel,1 Yuliya Naumchuk,1 Alexander Zabaneh,1 Bryan C Gerdes,1 Nancy Kunjukunju,1 Nelson R Sabates,1 Michael A Cassell,1 Ron K Lord,1 Kevin P Pikey,1 Abraham Poulose,1 Peter Koulen1,21Vision Research Center, Department of Ophthalmology, 2Department of Basic Medical Science, School of Medicine, University of Missouri – Kansas City, Kansas City, MO, USA*These authors contributed equally to this workAbstract: The main objective of the study was to quantify serum levels of nicotinamide phosphoribosyltransferase (Nampt/pre-B-Cell colony-enhancing factor 1/visfatin) in subjects with a history of retinal vascular occlusions (RVOs), disease conditions characterized by pronounced ischemia, and metabolic energy deficits. A case–control study of 18 subjects with a history of RVO as well as six healthy volunteers is presented. Serum Nampt levels were quantified using a commercially available enzyme-linked immunosorbent assay kit. Serum Nampt levels were 79% lower in patients with a history of RVO compared with that in healthy volunteers (P<0.05). There was no statistically significant difference among the types of RVOs, specifically branch retinal vein occlusions (n=7), central retinal vein occlusions (n=5), hemiretinal vein occlusions (n=3), and central retinal artery occlusions (n=3; P=0.69). Further studies are needed to establish the temporal kinetics of Nampt expression and to determine whether Nampt may represent a novel biomarker to identify at-risk populations, or whether it is a druggable target with the potential to ameliorate the long-term complications associated with the condition, ie, macular edema, macular ischemia, neovascularization, and permanent loss of vision.Keywords: Nampt, PBEF, visfatin, nicotinamide phosphoribosyltransferase, pre-B-cell colony-enhancing factor, retinal artery occlusion, retinal vein occlusion, biomarker, retina, vasculature |
| format |
article |
| author |
Kaja S Shah AA Haji SA Patel KB Naumchuk Y Zabaneh A Gerdes BC Kunjukunju N Sabates NR Cassell MA Lord RK Pikey KP Poulose A Koulen P |
| author_facet |
Kaja S Shah AA Haji SA Patel KB Naumchuk Y Zabaneh A Gerdes BC Kunjukunju N Sabates NR Cassell MA Lord RK Pikey KP Poulose A Koulen P |
| author_sort |
Kaja S |
| title |
Nampt/PBEF/visfatin serum levels: a new biomarker for retinal blood vessel occlusions |
| title_short |
Nampt/PBEF/visfatin serum levels: a new biomarker for retinal blood vessel occlusions |
| title_full |
Nampt/PBEF/visfatin serum levels: a new biomarker for retinal blood vessel occlusions |
| title_fullStr |
Nampt/PBEF/visfatin serum levels: a new biomarker for retinal blood vessel occlusions |
| title_full_unstemmed |
Nampt/PBEF/visfatin serum levels: a new biomarker for retinal blood vessel occlusions |
| title_sort |
nampt/pbef/visfatin serum levels: a new biomarker for retinal blood vessel occlusions |
| publisher |
Dove Medical Press |
| publishDate |
2015 |
| url |
https://doaj.org/article/beebcfe6aec644fb9aa15fde17ab5a88 |
| work_keys_str_mv |
AT kajas namptpbefvisfatinserumlevelsanewbiomarkerforretinalbloodvesselocclusions AT shahaa namptpbefvisfatinserumlevelsanewbiomarkerforretinalbloodvesselocclusions AT hajisa namptpbefvisfatinserumlevelsanewbiomarkerforretinalbloodvesselocclusions AT patelkb namptpbefvisfatinserumlevelsanewbiomarkerforretinalbloodvesselocclusions AT naumchuky namptpbefvisfatinserumlevelsanewbiomarkerforretinalbloodvesselocclusions AT zabaneha namptpbefvisfatinserumlevelsanewbiomarkerforretinalbloodvesselocclusions AT gerdesbc namptpbefvisfatinserumlevelsanewbiomarkerforretinalbloodvesselocclusions AT kunjukunjun namptpbefvisfatinserumlevelsanewbiomarkerforretinalbloodvesselocclusions AT sabatesnr namptpbefvisfatinserumlevelsanewbiomarkerforretinalbloodvesselocclusions AT cassellma namptpbefvisfatinserumlevelsanewbiomarkerforretinalbloodvesselocclusions AT lordrk namptpbefvisfatinserumlevelsanewbiomarkerforretinalbloodvesselocclusions AT pikeykp namptpbefvisfatinserumlevelsanewbiomarkerforretinalbloodvesselocclusions AT poulosea namptpbefvisfatinserumlevelsanewbiomarkerforretinalbloodvesselocclusions AT koulenp namptpbefvisfatinserumlevelsanewbiomarkerforretinalbloodvesselocclusions |
| _version_ |
1718400074192519168 |